Day One Makes Jaa Roberson its New Chief People Officer

Jaa Roberson has worked in the biopharmaceutical, health insurance, and retail industries for the past 20 years.

FREMONT, CA: Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company devoted to developing and commercializing targeted therapies for patients across all ages with genomically defined cancers, recently appointed Jaa Roberson as its new chief people officer. Jaa will be in charge of all areas of Day One's human resources and talent acquisition operations in her new job.

"Day One is built on a foundation of talented employees who share a strong commitment and passion for developing innovative targeted therapies to improve the lives of children and people of all ages living with cancer," said Jeremy Bender, Ph.D., Chief Executive Officer, Day One. "We could not be more excited to welcome Jaa to our senior leadership team. As the Company continues to grow and scale, we are confident that her deep experience in human resources and talent acquisition will contribute to our future success."

Jaa has worked in the biopharmaceutical, health insurance, and retail industries for the past 20 years. She most recently worked for Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical business specializing in cellular immuno-oncology. Furthermore, she formerly worked for Achaogen as the chief of human resources. She worked at Genentech/Roche for six years, supporting the commercial business units for cancer, IMPACT, immunology, and ophthalmology. Jaa formerly worked in human resources at Blue Shield of California, Levi Strauss & Company, and Williams-Sonoma. She holds a bachelor's degree in arts from Rice University and a master's degree in violin performance from the San Francisco Conservatory of Music.

"This is a company and team that I feel privileged to join," said Jaa. "I will continue to build on the spirited and dynamic culture at Day One as we work together toward our common objective of providing children and patients of all ages with important new targeted cancer treatments."